tiprankstipranks
Trending News
More News >
Advertisement
Advertisement

Immix Biopharma announces ‘class-leading’ safety profile for NXC-201

Immix Biopharma (IMMX) announced a “class-leading” safety profile for sterically-optimized CAR-T NXC-201, including absence of neurotoxicity of any grade in low-volume disease to-date, laying a foundation for potential future indication expansion. “We are singularly focused on completing NEXICART-2 for BLA submission, where we are accelerating progress. Separately and subsequently, for potential future expansion directions, we believe NXC-201 will be able to address a range of immune-mediated and other serious diseases,” said Ilya Rachman, M.D., Ph.D., CEO of Immix Biopharma. Gabriel Morris, Chief Financial Officer of Immix Biopharma, added, “Our near-term efforts are laser- focused on our path to NEXICART-2 BLA submission for FDA approval.”

Elevate Your Investing Strategy:

  • Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.

Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>

Disclaimer & DisclosureReport an Issue

1